ArticleCureus2025
Successful Use of Venoarterial Extracorporeal Membrane Oxygenation in Acute Drug Intoxication: Three Cases From a Single Japanese Center.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The indications for extracorporeal membrane oxygenation (ECMO) have broadened in clinical practice, and its use in circulatory failure caused by acute drug intoxication has become more frequent. We reviewed three cases of venoarterial (VA) ECMO use for intoxication at our hospital. Three cases (aged 60-69 years) developed refractory shock following intentional overdose, including calcium channel blockers. Despite maximal pharmacologic support, all exhibited progressive hemodynamic deterioration and elevated serum lactate levels (max 8.0-20.0 mmol/L). VA ECMO was initiated on the day of admission in each case. Hemodynamic stability was restored, and ECMO was discontinued within 4 to 6 days. All patients survived hospital discharge without major ECMO-related complications. These cases highlight the potential benefit of the timely initiation of VA ECMO in selected intoxicated patients with drug-induced cardiogenic shock. Comparison with other clinical experiences suggests better outcomes when ECMO is implemented before cardiac arrest. Lactate levels at the time of ECMO initiation may serve as a prognostic indicator. The timely initiation of VA ECMO may be life-saving in patients with acute drug intoxication and refractory cardiogenic shock. Careful patient selection, guided by toxin type and pre-ECMO lactate trends, is essential to optimize outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.